MX2017010363A - Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc). - Google Patents
Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc).Info
- Publication number
- MX2017010363A MX2017010363A MX2017010363A MX2017010363A MX2017010363A MX 2017010363 A MX2017010363 A MX 2017010363A MX 2017010363 A MX2017010363 A MX 2017010363A MX 2017010363 A MX2017010363 A MX 2017010363A MX 2017010363 A MX2017010363 A MX 2017010363A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- isochromanyl
- heterocyclyl
- analogs
- cns disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen compuestos de la Fórmula (I): (ver Fórmula) y sales farmacéuticamente aceptables de los mismos, en donde A, Ra R1, R2, R3, R4, R6, w y n1 se definen y describen en la presente; composiciones de los mismos; y métodos de uso de los mismos. Estos compuestos son útiles para tratar una variedad de trastornos neurológicos y psiquiátricos, tales como los descritos aquí.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115064P | 2015-02-11 | 2015-02-11 | |
| PCT/US2016/017539 WO2016130796A1 (en) | 2015-02-11 | 2016-02-11 | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017010363A true MX2017010363A (es) | 2018-05-04 |
| MX371404B MX371404B (es) | 2020-01-29 |
Family
ID=55456908
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001157A MX2020001157A (es) | 2015-02-11 | 2016-02-11 | Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc). |
| MX2017010363A MX371404B (es) | 2015-02-11 | 2016-02-11 | Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc). |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001157A MX2020001157A (es) | 2015-02-11 | 2016-02-11 | Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc). |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US9856238B2 (es) |
| EP (2) | EP4046995B1 (es) |
| JP (3) | JP6657241B2 (es) |
| KR (1) | KR102601972B1 (es) |
| CN (2) | CN111925360B (es) |
| AU (1) | AU2016219253C1 (es) |
| CA (1) | CA2976095C (es) |
| DK (1) | DK3256466T3 (es) |
| EA (1) | EA201791804A1 (es) |
| ES (2) | ES2967643T3 (es) |
| HU (1) | HUE058698T2 (es) |
| IL (1) | IL253914B (es) |
| MX (2) | MX2020001157A (es) |
| MY (1) | MY188160A (es) |
| NZ (1) | NZ735011A (es) |
| PH (1) | PH12017501422A1 (es) |
| PL (1) | PL3256466T3 (es) |
| PT (1) | PT3256466T (es) |
| SG (2) | SG11201706515QA (es) |
| UA (1) | UA122222C2 (es) |
| WO (1) | WO2016130796A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201706516WA (en) * | 2015-02-11 | 2017-09-28 | Sunovion Pharmaceuticals Inc | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders |
| EP4046995B1 (en) * | 2015-02-11 | 2023-09-13 | Sunovion Pharmaceuticals Inc. | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
| EP3490607A4 (en) | 2016-07-29 | 2020-04-08 | Sunovion Pharmaceuticals Inc. | COMPOUNDS AND COMPOSITIONS, AND USES THEREOF |
| MA45857A (fr) * | 2016-07-29 | 2021-05-19 | Sunovion Pharmaceuticals Inc | Composés et compositions, et utilisations associées |
| CN111032158A (zh) | 2017-06-30 | 2020-04-17 | 才思治疗公司 | 用于治疗抑郁的nk-1拮抗剂组合物和方法 |
| JP7191085B2 (ja) | 2017-08-02 | 2022-12-16 | サノビオン ファーマシューティカルズ インク | イソクロマン化合物およびその使用 |
| EP3938045A1 (en) | 2019-03-14 | 2022-01-19 | Sunovion Pharmaceuticals Inc. | Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3438995A (en) | 1968-01-08 | 1969-04-15 | Melville Sahyun | Diazaheterocyclic substituted benz-oxaheterocyclic compounds |
| US5621133A (en) | 1989-05-31 | 1997-04-15 | Deninno; Michael P. | Dopamine agonists |
| US4963568A (en) | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| IE73232B1 (en) * | 1990-05-25 | 1997-05-21 | Akzo Nv | Isochromane derivatives |
| US5238939A (en) * | 1990-05-25 | 1993-08-24 | Akzo N.V. | Isochromane derivatives |
| JP2002519348A (ja) | 1998-06-30 | 2002-07-02 | イーライ・リリー・アンド・カンパニー | ５−ｈｔ１ｆアゴニスト |
| SE9902267D0 (sv) | 1999-06-16 | 1999-06-16 | Astra Ab | New compounds |
| MXPA04004368A (es) * | 2001-11-08 | 2004-08-11 | Sepracor Inc | Metodos para tratar depresion y otros transtornos del sistema nervioso central utilizando desmetil-y didesmetil-metabolitos del citalopram enantiomericamente enriquecidos. |
| JP4738418B2 (ja) * | 2004-12-21 | 2011-08-03 | エフ．ホフマン−ラ ロシュ アーゲー | クロマン誘導体及びｃｎｓ障害の処置におけるその使用 |
| RU2007139541A (ru) | 2005-04-22 | 2009-05-27 | Вайет (Us) | Производные хромана и хромена и их применение |
| EP1981499A1 (en) * | 2006-01-27 | 2008-10-22 | F.Hoffmann-La Roche Ag | Use of 2-imidazoles for the treatment of cns disorders |
| KR101103118B1 (ko) | 2007-11-02 | 2012-01-04 | 동아제약주식회사 | 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물 |
| RU2707067C2 (ru) | 2009-12-04 | 2019-11-22 | Суновион Фармасьютикалз, Инк. | Полициклические соединения и способы их применения |
| EP2683710B1 (en) | 2011-03-10 | 2017-07-19 | Boehringer Ingelheim International GmbH | Soluble guanylate cyclase activators |
| AR090557A1 (es) | 2012-04-02 | 2014-11-19 | Orion Corp | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 |
| CA2896871A1 (en) * | 2012-12-31 | 2014-07-03 | Kerry L. Spear | Heterocyclic compounds and methods of use thereof |
| EP4046995B1 (en) * | 2015-02-11 | 2023-09-13 | Sunovion Pharmaceuticals Inc. | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
-
2016
- 2016-02-11 EP EP22166538.3A patent/EP4046995B1/en active Active
- 2016-02-11 CA CA2976095A patent/CA2976095C/en active Active
- 2016-02-11 ES ES22166538T patent/ES2967643T3/es active Active
- 2016-02-11 SG SG11201706515QA patent/SG11201706515QA/en unknown
- 2016-02-11 EA EA201791804A patent/EA201791804A1/ru unknown
- 2016-02-11 MY MYPI2017702923A patent/MY188160A/en unknown
- 2016-02-11 EP EP16708262.7A patent/EP3256466B9/en active Active
- 2016-02-11 PT PT167082627T patent/PT3256466T/pt unknown
- 2016-02-11 AU AU2016219253A patent/AU2016219253C1/en active Active
- 2016-02-11 PL PL16708262T patent/PL3256466T3/pl unknown
- 2016-02-11 MX MX2020001157A patent/MX2020001157A/es unknown
- 2016-02-11 WO PCT/US2016/017539 patent/WO2016130796A1/en active Application Filing
- 2016-02-11 US US15/041,852 patent/US9856238B2/en active Active
- 2016-02-11 SG SG10201806809QA patent/SG10201806809QA/en unknown
- 2016-02-11 CN CN202010607608.6A patent/CN111925360B/zh active Active
- 2016-02-11 KR KR1020177025290A patent/KR102601972B1/ko active IP Right Grant
- 2016-02-11 NZ NZ735011A patent/NZ735011A/en unknown
- 2016-02-11 CN CN201680018639.XA patent/CN107531674B/zh active Active
- 2016-02-11 MX MX2017010363A patent/MX371404B/es active IP Right Grant
- 2016-02-11 DK DK16708262.7T patent/DK3256466T3/da active
- 2016-02-11 JP JP2017542401A patent/JP6657241B2/ja active Active
- 2016-02-11 HU HUE16708262A patent/HUE058698T2/hu unknown
- 2016-02-11 UA UAA201708945A patent/UA122222C2/uk unknown
- 2016-02-11 ES ES16708262T patent/ES2911910T3/es active Active
-
2017
- 2017-08-08 IL IL253914A patent/IL253914B/en unknown
- 2017-08-09 PH PH12017501422A patent/PH12017501422A1/en unknown
- 2017-11-21 US US15/819,372 patent/US10336732B2/en active Active
-
2019
- 2019-05-06 US US16/403,698 patent/US11192885B2/en active Active
-
2020
- 2020-02-05 JP JP2020018081A patent/JP7023994B2/ja active Active
-
2021
- 2021-10-29 US US17/452,786 patent/US20220185799A1/en active Pending
-
2022
- 2022-02-09 JP JP2022018580A patent/JP2022065050A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501422A1 (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| PH12017501423A1 (en) | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders | |
| MX2022012313A (es) | Oxisteroles y metodos de uso de los mismos. | |
| PH12018500065A1 (en) | Oxysterols and methods of use thereof | |
| PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
| MX2023005098A (es) | Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central. | |
| MX2023002006A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX2022005160A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MX2023001876A (es) | Derivados de rapamicina. | |
| EP4316591A3 (en) | Oxysterols and methods of use thereof | |
| MX2016010056A (es) | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| MX2015012389A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a. | |
| PH12017501876A1 (en) | Pyridopyrimidones and their use as nmda receptor modulators | |
| NZ748942A (en) | Pyrazolylaminobenzimidazole derivatives as jak inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |